Merck: launches Phase 3 trial
(CercleFinance.com) - On Tuesday, Merck announced the launch of a Phase 3 clinical trial designed to evaluate the efficacy of bomedemstat, a small oral molecule, in the treatment of essential thrombocythemia, a disease characterized by excessive platelet production.
The US biopharmaceutical group reports that it has begun recruiting patients, with the aim of enrolling around 300 individuals in the study.
This aims to compare the efficacy of bomedemstat with the current standard treatment of the disease, which consists of hydroxyurea chemotherapy, in people who have not undergone cytoreduction.
Merck explains that this treatment has not changed for several decades, and that patients suffering from this pathology need new therapies.
Essential thrombocythemia is characterized by excessive platelet production, leading to coagulation abnormalities such as blood clots or bleeding.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The US biopharmaceutical group reports that it has begun recruiting patients, with the aim of enrolling around 300 individuals in the study.
This aims to compare the efficacy of bomedemstat with the current standard treatment of the disease, which consists of hydroxyurea chemotherapy, in people who have not undergone cytoreduction.
Merck explains that this treatment has not changed for several decades, and that patients suffering from this pathology need new therapies.
Essential thrombocythemia is characterized by excessive platelet production, leading to coagulation abnormalities such as blood clots or bleeding.
Copyright (c) 2024 CercleFinance.com. All rights reserved.